Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Bladder Cancer and Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
Immune checkpoint inhibitors have revolutionized the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to advanced disease, the anti-PD-1…
Colorectal Cancer – Unmet Need – Unmet Need – Previously treated BRAF-mutant or RAS-mutant metastatic colorectal cancer (US/EU)
The treatment landscape for second- and later-line metastatic colorectal cancer with BRAF or RAS mutations is rapidly changing following the market entry of biomarker-specific combination therapies…
Non-Small-Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Non-Small-Cell Lung Cancer (US)
Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. In 2024, Imfinzi…
Non-Small-Cell Lung Cancer – Current Treatment – Treatment Sequencing – Non-Small-Cell Lung Cancer (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Small-Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Small-Cell Lung Cancer (US)
The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. The immune checkpoint inhibitors Tecentriq (Roche; FDA approved in 2019) and Imfinzi (…
Small-Cell Lung Cancer – Current Treatment – Treatment Sequencing – Small-Cell Lung Cancer (US)
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
Breast Cancer – Unmet Need – Unmet Need – Metastatic Triple-Negative Breast Cancer (US/EU)
The treatment of metastatic triple-negative breast cancer is rapidly evolving with new combination therapies and biomarker-driven approaches. Immunotherapies such as Keytruda (Merck & Co.) have…
Hepatocellular Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The hepatocellular carcinoma therapy market is experiencing substantial growth. Angiogenesis inhibitors have played a central role in treating advanced disease, but the approval of immunotherapies…
Malignant Melanoma – Current Treatment – Current Treatment: Physician Insights – Malignant Melanoma (US)
Disease stage, primary tumor resectability, and BRAF mutation status are some of the key parameters influencing the treatment of malignant melanoma. For patients with BRAF mutations, BRAF/MEK…
Malignant Melanoma – Current Treatment – Treatment Sequencing – Malignant Melanoma (US)
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
Breast Cancer – Current Treatment – Current Treatment: Physician Insights – Breast Cancer (US)
The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) plus endocrine therapy are entrenched first-line…
